Search

Understanding spaceflight-associated neuro-ocular syndrome (SANS): what do we know?

Introduction Formerly known as visual impairment and intracranial pressure syndrome (VIIP), space-related neuro-ocular syndrome (SANS) is defined by a collection of ophthalmic and neurological findings in astronauts after long-term spaceflight [1]. Changes in the eyeball, such as hyperopic shift, during...

AI & Oculomics: a new section for Eye News

Inaugurating this new regular section on the exciting landscape of AI and oculomics, we provide an overview which delves into the historical context and the etymology of this field, reviews the current state of play and contemplates possibilities and hopes...

Optic nerve swelling – your survival guide (part 1)

Assessment of optic nerve appearance and functions is a daily routine in neuro-ophthalmology. Following a recent high profile court case there has been a significant increase in the amount of referral to ophthalmology departments to assess the optic nerve and...

Therapy for limbal stem cell deficiency: cell fate after limbal stem cell transplants

“The beauty of scientific research lies in that the search for answers often yields yet more questions.” A large body of evidence points to the corneoscleral limbal location as the repository of putative epithelial stem cells [1]. Thoft proposed the...

NICE drugs: an update on what’s good to go

Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...

Advances and developments in medical retina

The author provides an update on late breaking clinical trial results in neovascular age-related macular degeneration (nAMD) and presentations on diabetes management from the American Academy of Ophthalmology Retina Subspecialty Day, held during the Academy’s annual meeting in Chicago, October...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

Update on emerging therapies for age-related macular degeneration

The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...

Redefining healthcare through the eyes

The future of healthcare is being shaped by innovation in eyecare and in particular a field known as oculomics. This discipline leverages ocular biomarkers to provide insights into various health conditions, including cardiovascular diseases and psychological or neurological disorders [1]....

How the development of Glaucoma Guidelines, Glaucoma Toolkit and GLASS training and the Glaucoma nurse training can effect change in Nigeria

In July 2024, a combined training, led by Fatima Kyari, was run in Abuja, Nigeria to facilitate a multifaceted upskilling in glaucoma management. The first week comprised of inviting 36 doctors practising glaucoma from around Nigeria’s 36 states, including the...